Ayala Pharmaceuticals (ADXS) announced the completion of the previously announced sale of AL102, and related drug candidate AL101, to Immunome (IMNM). As per the terms of the sale, Ayala received from Immunome $20 million in cash and 2,175,489 shares of Immunome common stock, and Immunome assumed specified liabilities related to AL102. Ayala may also receive up to an additional $37.5 million in development and commercial milestone payments.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADXS: